Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir

Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir

Abstract COVID‐19 in cancer patients on immunosuppressive agents for the treatment of immune‐related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID‐19, and furthe...

Full description

Bibliographic Details
Main Authors: Naohiro Oda, Keiji Miyoshi, Daisuke Morichika, Yuka Beika, Takahiro Taki, Reo Mitani, Toshiaki Okada, Ichiro Takata
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Clinical Case Reports
Subjects:
baricitinib
COVID‐19
immune checkpoint inhibitor
immune‐related adverse event
lung cancer
Online Access:https://doi.org/10.1002/ccr3.4459

Similar Items

Similar Items